ERBB3 and pancreatic neoplasm: Conversely, pertuzumab had no significant effect on shHER3 BxPC-3 cell growth (Figure 3C), demonstrating that HER3 knockdown in vitro induces resistance to pertuzumab therapy in pancreatic cancer cells.